Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

5 years ago
R&D
Special

Top 10 pipeline blowups, set­backs and sna­fus in H1 2018

5 years ago
R&D
Special

Vant com­man­der Ra­maswamy heads back to Nas­daq with a $150M pitch — are in­vestors ready to for­give Ax­o­vant?

5 years ago
Financing

12 top Chi­na VCs you need to know who are mak­ing a transpa­cif­ic splash (Part 2)

5 years ago
Financing
China

RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing down

5 years ago
Financing
Startups

What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M

5 years ago
Financing

The 2-tri­al hur­dle for drug ap­provals is steadi­ly los­ing ground. Are we de­valu­ing the in­dus­try's R&D gold stan­dard?

5 years ago
Bioregnum
Opinion

Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

6 years ago
Discovery
In Focus

The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018

6 years ago
R&D
Special

Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

6 years ago
R&D

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

6 years ago
Financing

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

6 years ago
Financing
Special

The class of 2017's win­ners and losers: A year of 'non­stop sci­en­tif­ic achieve­ments' rais­es trou­bling is­sues

6 years ago
Special
Pharma

Bio­phar­ma's top 10 over­seas cash hoards. And what kind of M&A spree would $171B buy?

6 years ago
Deals

The top 10 hit pa­rade of bio­phar­ma li­cens­ing deals for 2014-2017

6 years ago
Pharma

Who are the top 10 play­ers that dom­i­nate the can­cer drug mar­ket? And who's grow­ing fastest?

6 years ago
R&D
Pharma

In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

6 years ago

R&D trend #5: The top ex­ecs in biotech are rid­ing a boom — but there’s one big step left

6 years ago

Top trend #4: We’re com­ing to a tip­ping point on can­cer R&D, and it may not be pret­ty

6 years ago
R&D

The top 5 trends in biotech - #3: High val­u­a­tions for at­trac­tive biotechs are a durable symp­tom of a thriv­ing fi­nanc­ing are­na

6 years ago

How En­ter­prise cus­tomers can get End­points News in­to their Slack

6 years ago
Publisher's note

Top 5 bio­phar­ma trends: The long-await­ed bio­phar­ma rev­o­lu­tion in Chi­na has ar­rived — don’t lose out

6 years ago
China

The top 5 trends re­shap­ing bio­phar­ma starts with an R&D earth­quake

6 years ago
First page Previous page 20212223